Barclays
BCAX

Barclays’s Bicara Therapeutics BCAX Stock Holding History

Barclays’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$573K Sell
28,823
-74,418
-72% -$1.28M ﹤0.01% 3109
2025
Q4 		$1.74M Buy
103,241
+55,093
+114% +$941K ﹤0.01% 3041
2025
Q3 		$760K Sell
48,148
-9,186
-16% -$103K ﹤0.01% 3534
2025
Q2 		$533K Buy
57,334
+37,063
+183% +$442K ﹤0.01% 3726
2025
Q1 		$264K Sell
20,271
-9,836
-33% -$131K ﹤0.01% 3897
2024
Q4 		$524K Buy
30,107
+20,107
+201% +$418K ﹤0.01% 3795
2024
Q3 		$255K Buy
+10,000
New +$255K ﹤0.01% 4175

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Barclays's BCAX Position: Q1 2026 in Review

Barclays reduced its Bicara Therapeutics (BCAX) stake by 72% in Q1 2026, selling an estimated $1.28M and leaving 28,823 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #3109.

Barclays first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.74M in Q4 2025. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Barclays held 28,823 shares of Bicara Therapeutics worth $573K as of Q1 2026.
  • Barclays sold 74,418 Bicara Therapeutics shares in Q1 2026, an estimated $1.28M.
  • Bicara Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3109 holding.
  • Barclays first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Barclays's Bicara Therapeutics position peaked at $1.74M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.